BTIG Research Boosts OrthoPediatrics (NASDAQ:KIDS) Price Target to $29.00

OrthoPediatrics (NASDAQ:KIDS) had its price target lifted by investment analysts at BTIG Research from $24.00 to $29.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 9.43% from the stock’s current price.

Several other analysts have also weighed in on the stock. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group set a $25.00 target price on shares of OrthoPediatrics in a report on Friday, April 24th. Truist Financial set a $22.00 price target on OrthoPediatrics in a report on Wednesday, August 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Finally, Needham & Company LLC boosted their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $26.44.

OrthoPediatrics Trading Up 3.9%

NASDAQ:KIDS opened at $26.50 on Thursday. The company has a market cap of $691.91 million, a PE ratio of -15.77 and a beta of 0.98. The business’s 50 day moving average is $20.53 and its two-hundred day moving average is $18.29. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. OrthoPediatrics has a 52 week low of $14.42 and a 52 week high of $26.71.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. On average, analysts predict that OrthoPediatrics will post -1.14 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of KIDS. AIGH Capital Management LLC bought a new position in OrthoPediatrics in the 2nd quarter valued at about $5,161,000. Wasatch Advisors LP raised its holdings in OrthoPediatrics by 56.6% during the second quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock worth $9,865,000 after purchasing an additional 186,357 shares in the last quarter. Roubaix Capital LLC boosted its stake in OrthoPediatrics by 23.8% during the 1st quarter. Roubaix Capital LLC now owns 290,047 shares of the company’s stock valued at $4,603,000 after purchasing an additional 55,724 shares in the last quarter. Granahan Investment Management LLC boosted its stake in OrthoPediatrics by 35.1% during the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after buying an additional 232,760 shares in the last quarter. Finally, BlackRock Inc. bought a new position in shares of OrthoPediatrics during the 2nd quarter valued at about $24,347,000. Institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.